Metabolic interrelationships, cardiovascular disease, and sex steroids

被引:3
作者
Fotherby, K [1 ]
机构
[1] Royal Postgrad Med Sch, London W12 0NN, England
关键词
pharmacodynamic studies of oral contraceptives; lipid metabolism; cardiovascular disease; sex steroids;
D O I
10.1016/S0010-7824(98)00017-1
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Future studies of the pharmacodynamics of oral contraceptives should encompass interactions between various areas of physiology rather than concentrate on single metabolic processes. Changes in one area of metabolism may affect other areas. Insulin plays a central role in metabolic control and, in addition to profound effects on carbohydrate and lipid metabolism, also affects the hematological system. Insulin has been proposed as a major physiological regulator of plasminogen activator inhibitor, and hyperinsulinemia is associated with increased blood coagulability and decreased fibrinoloysis. There is a close relationship between insulin and triglyceride metabolism, and this may affect factor VII activity in blood. There are many interactions between lipid metabolism and hematological factors. The apoprotein of lipoprotein (a) is structurally similar to plasminogen. Tissue factor pathway inhibitor, a regulator of coagulation, circulates in blood bound to LDL and HDL. Some fatty acids may act as a contact surface for activation of hematological factors. Dietary factors also need to be considered. Changes not only in the quantity but also in the composition of dietary fat influence lipid metabolism and also blood levels of a number of hematological factors. Other aspects of pharmacodynamic studies that require consideration and other factors that affect metabolic inter relationships are discussed. (C) 1998 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:183 / 187
页数:5
相关论文
共 20 条
[1]   Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes [J].
Austin, MA ;
Edwards, KL .
CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (03) :167-171
[2]   HAS LIPOPROTEIN LITTLE-(A) SHRUNK [J].
BARNATHAN, ES .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (18) :2224-2225
[3]   Lp(a) lipoprotein and risk of atherosclerotic/thrombotic disease [J].
Berg, K .
FIBRINOLYSIS & PROTEOLYSIS, 1997, 11 :71-75
[4]  
BLADBJERG EM, 1996, THESIS S JUTLAND U P
[5]  
Despres J.-P., 1991, Curr Opin Lipidol, V2, P5
[6]  
GOODNIGHT SH, 1990, CURR OPIN LIPIDOL, V1, P334
[7]   LIPOPROTEIN(A) IN CORONARY HEART-DISEASE - IS IT A RISK FACTOR AFTER ALL [J].
GUREWICH, V ;
MITTLEMAN, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (13) :1025-1026
[8]   Hypertension, dyslipidemia, and insulin resistance: Links in a chain or spokes on a wheel? [J].
Hopkins, PN ;
Hunt, SC ;
Wu, LL ;
Williams, GH ;
Williams, RR .
CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (04) :241-253
[9]   EFFECTS OF FATS AND FATTY-ACIDS ON BLOOD-LIPIDS IN HUMANS - AN OVERVIEW [J].
KATAN, MB ;
ZOCK, PL ;
MENSINK, RP .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1994, 60 (06) :1017S-1022S
[10]  
Kostner G. M., 1992, CURR OPIN LIPIDOL, V3, P279